 Beam Therapeutics Inc NASDAQ: BEAM joins forces with Apellis Pharmaceuticals Inc NASDAQ: APLS to create new gene-editing treatments for complement-driven diseases. The partnership will leverage Beams base-editing technology to discover new treatments against various targets in the complement system. 